Data from a registrational clinical trial of Jacobio Pharma's glecirasib, a KRAS G12C inhibitor, has been published in Nature Medicine, highlighting its efficacy in treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. The pivotal phase II trial results showcase the potential of glecirasib as a second-line or above treatment option for this patient population.
The study revealed a confirmed objective response rate (ORR) of 47.9% (56 out of 117 patients) with glecirasib monotherapy. Additionally, the median progression-free survival (mPFS) was 8.2 months, and the median overall survival (mOS) reached 13.6 months. These findings suggest a clinically meaningful benefit for patients with advanced NSCLC harboring the KRAS G12C mutation.
Glecirasib also demonstrated a manageable safety profile, with a favorable gastrointestinal safety profile compared to other KRAS G12C inhibitors. This is a crucial consideration for patients undergoing cancer treatment, as gastrointestinal toxicities can significantly impact quality of life.
Ongoing Development and Future Directions
The new drug application (NDA) for glecirasib is currently under evaluation by the Center for Drug Evaluation of the National Medical Products Administration of China and has been granted Priority Review Designation, potentially expediting its availability to patients in China.
"It's our great honor to present the data from our pivotal trial in such a prestigious journal as Nature Medicine," said Dr. Yinxiang Wang, Chairman and CEO of Jacobio Pharma. He further emphasized the ongoing efforts to develop KRAS-related inhibitors and the exploration of combination therapies, including glecirasib with the SHP2 inhibitor JAB-3312, for first-line NSCLC treatment. Jacobio Pharma is also advancing its other RAS programs, such as a Pan-KRAS inhibitor.
About Glecirasib
Glecirasib is a KRAS G12C inhibitor developed by Jacobio Pharma. Clinical trials are ongoing in China, the United States, and Europe, evaluating glecirasib in patients with advanced solid tumors harboring KRAS G12C mutations. These trials include combination therapies with the SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has received orphan drug designation in the United States and breakthrough therapy designation in China.
